oasis 4 semaglutide 25 mg Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) ADA 2026 - Cardiometabolic effects

Appetite and energy effects can appear within a few weeks, but meaningful weight change usually takes two to three months at the target dose

Body composition continues changing even when weight stalls

The tier placement is not listed in patient-facing formulary documents

Therefore, a multimodal approach may be necessary when treating COVID-19 in elderly patients or in those with preexisting conditions

Trends Cardiovasc Med 33(3):159166 De Hollanda BA, Prizo VM, de Souza MD, Mendes BX, Defante ML, Martins OC, Rodrigues AM (2024) The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: a meta-analysis of randomized controlled trials

People with obesity might face judgment from others and find daily activities harder